Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Archive ouverte

Oaknin, Ana | Gladieff, Laurence | Martínez-García, Jerónimo | Villacampa, Guillermo | Takekuma, Munetaka | de Giorgi, Ugo | Lindemann, Kristina | Woelber, Linn | Colombo, Nicoletta | Duska, Linda | Leary, Alexandra | Godoy-Ortiz, Ana | Nishio, Shin | Angelergues, Antoine | Rubio, Maria Jesús | Fariñas-Madrid, Lorena | Yamaguchi, Satoshi | Lorusso, Domenica | Ray-Coquard, Isabelle | Manso, Luis | Joly, Florence | Alarcón, Jesús | Follana, Philippe | Romero, Ignacio | Lebreton, Coriolan | Pérez-Fidalgo, J Alejandro | Yunokawa, Mayu | Dahlstrand, Hanna | d'Hondt, Véronique | Randall, Leslie | Abadie-Lacourtoisie, Sophie | Andreetta, Claudia | Anzizar, Nerea | Aoki, Daiseuke | Barretina-Ginesta, Maria-Pilar | Battista, Marco | Bellier, Charlotte | Bentzen, Anne Gry | Berton, Dominique | Billemont, Bertrand | Bjørge, Line | Bjurberg, Maria | Black, Destin | Bologna, Alessandra | Braicu, Elena Ioana | Casanova, Claudia | Chekerov, Radoslav | Chevalier, Annick | Cueva, Juan Fernando | Czogalla, Bastian | Delanoy, Nicolas | Denschlag, Dominik | Derke, Oscar | Eichbaum, Michael | Enomoto, Takayuki | Esteban, Carmen | Fabbro, Michel | Fehm, Tanja | Ferrero, Annamaria | Fleisch, Markus | Floquet, Anne | Frassoldati, Antonio | Gaba, Lydia | Gadducci, Angiolo | García, Yolanda | Geuna, Elena | Guerra, Eva | Hanker, Lars | Hardy-Bessard, Anne-Claire | Harter, Philipp | Hasegawa, Kosei | Hellman, Kristina | Herrero, Ana | Hilpert, Felix | Katsaros, Dionyssios | Koegel, Matthias | Koliadi, Anthoula | Kurtz, Jean-Emmanuel | Lampe, Bjoern | Lissoni, Andrea Alberto | Lortholary, Alain | Mangili, Giorgia | Mansi, Laura | Marmé, Frederik | Mathews, Cara | Mina, William | Minobe, Shinichiro | Moxley, Katherine | Nagao, Shoji | Nicoletto, Ornella | Nishino, Koji | Nishio, Hiroshi | Onstad, Michaela | Pardo, Beatriz | Pisano, Carmela | Poveda, Andrés | Radosa, Julia | Redondo, Andrés | Richardson, Debra | Ronzino, Graziana | Selle, Frederic | Takeshima, Nobuhiro | Tasca, Giulia | Tewari, Krishnansu | Todo, Yukiharu | Valabrega, Giorgio | Wimberger, Pauline | You, Benoît

Edité par CCSD ; Elsevier -

International audience. The GOG240 trial established bevacizumab with chemotherapy as standard first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10-GEICO 68-C-JGOG1084-GOG-3030), we aimed to evaluate the addition of an immune checkpoint inhibitor to this standard backbone.

Consulter en ligne

Suggestions

Du même auteur

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial

Archive ouverte | Harter, P. | CCSD

International audience. The use of first-line poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is increasing in advanced ovarian cancer. Understanding the efficacy of first subsequent therapy (FST) i...

Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup

Archive ouverte | Creutzberg, Carien | CCSD

International audience. The Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Consensus Conference on Clinical Research (ECCC) was held in Incheon, South Korea, Nov 2-3, 2023. The aims were to develop consensu...

739P Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial. L’année 2021 dans tous ses états : une synthèse digérée

Archive ouverte | Sabatier, Renaud | CCSD

International audience. 5548 Background: Ovarian cancer is the leading cause of death by gynecological cancer. Complete surgery remains one of the main prognostic factors. Laparoscopic exploration is mandatory to as...

Chargement des enrichissements...